Concurrent CIS-platinum and radiation with or without surgery for advanced head and neck cancer

Cisplatinum and interstitial laser therapy for advanced head and neck cancer: A preclinical study

“…SCCA tumor transplants with initial volumes of 400-600 mm 3 continued to grow for 10 weeks to 8-fold increased average size ( Fig. 1).…”

“…Tumor volume was measured with vernier calipers using the formula V ‫ס‬ 2/3 (L × W × H). P3 tumors required approximately 4 weeks to grow to a size of 400-600 mm 3 , presenting little central necrosis and a good vascular supply at the time treatment was administered. Animals were weighed, tumors measured, and photographed weekly throughout the entire follow-up period of 10 weeks.…”

“…The animals were first anesthetized by an intraperitoneal injection of nembutal in ethanol. ILT was performed on sedated animals with 400-600 mm 3 tumors by fiberoptic implantation through the skin into the tumor. Laser energy was delivered to multiple tumor sites in a circumferential pincushion technique by activating the KTP laser for 5 sec/site at the periphery and 5 sec for each 2.5 mm depth in the tumor center.…”

“…More effective treatment should be possible by intraoperative combination therapy [1]. Use of the chemotherapeutic agent cisplatinum (CDDP) as an adjunct in the treatment of advanced head and neck cancer has shown promising response rates [3,4]. However, the effects of CDDP on long-term survival remains controversial, and tumor chemotherapy has been limited by systemic side effects includ-ing gastrointestinal toxicity, myelosuppression, and nephrotoxicity [5].…”

Hyperfractionated Accelerated Concomitant Boost With Weekly Cisplatin in Stage Iii and Stage Iva Cancers of Oropharynx and Hypopharynx

“…However, there was no difference in the incidence of persistent Grade III or Grade IV late toxicity among the arms at one year or longer followup. 10,11 In comparison with chemoradiation treatment strategies attempted in this Institution, this treatment protocol compares favourably of 61.6%. Another study that evaluated hyper-fractionated radiation therapy and concurrent Cisplatin-5FU chemotherapy (2 cycles, week 1 and 5) recorded a complete response of 73.1% and acute Grade III toxicity of 62%.…”